{"entity":{"id":"interius","kind":"company","name":"Interius BioTherapeutics","aka":[],"tldr":"Penn spin-out that dosed the first patient ever with a durable in vivo CAR gene therapy (INT2104, CD20) in the INVISE trial.","summary":"INT2104 is an engineered lentiviral vector that generates CAR-T and CAR-NK cells against CD20 after a single IV infusion, without lymphodepletion. Phase 1 INVISE in relapsed/refractory B-cell malignancies started in Australia (2024-25); preclinical large-animal data showed B-cell depletion without CRS or neurotoxicity.","asOf":"2026-09-04","links":[{"label":"First patient dosed","url":"https://interiusbio.com/press-release/interius-biotherapeutics-doses-first-patient-with-in-vivo-chimeric-antigen-receptor-car-gene-therapy-for-b-cell-malignancies/"}],"tags":["frontier"],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["in-vivo-car-t"],"targets":["cd20"],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Philadelphia, PA","country":"US","companyType":"cell-therapy","website":"https://interiusbio.com","investors":[],"funding":[]},"route":"/companies/interius/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"institution":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"idea":[{"id":"idea-reg-in-vivo-cart-off-the-shelf-vial","kind":"idea","name":"In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma","route":"/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/"},{"id":"idea-moon-in-vivo-cart-generic-price","kind":"idea","name":"In vivo CAR-T manufactured and priced like a generic biologic","route":"/ideas/idea-moon-in-vivo-cart-generic-price/"}]}}